Telaprevir and Boceprevir are protease inhibitors which belong to a class of agents known as DAA's, and are the two products currently in phase three development. |
A new standard of care has emerged with the regulatory approval of the protease inhibitors boceprevir and telaprevir. |
The study involves 54 patients receiving telaprevir in combination with peginterferon and another treatment, ribavirin. |
Since 2011, doctors sometimes added in the viral inhibitors boceprevir or telaprevir. |